Partial
Partly Aligned
Patient Risk:
Medium
Summary
The response accurately captures indication and endothelin receptor mechanism and generally reflects hepatotoxicity/monitoring concepts. However, multiple safety-critical claims (pregnancy contraindication and fetal risk details, breastfeeding recommendation, and several renal/hepatic/interaction specifics) are not supported by the supplied label excerpts, and some precaution-type statements appear under-supported or overstated relative to what is shown.
Category Scores
Accurate Statements
Bosentan is used to treat pulmonary arterial hypertension (PAH).
1 INDICATIONS AND USAGE: “TRACLEER is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1)…”
Bosentan works by blocking the action of endothelin-1.
12.1 Mechanism of Action: bosentan is “a specific and competitive antagonist at endothelin receptor types ET_A and ET_B”; ET-1 effects mediated via these receptors.
Bosentan is associated with an increase in liver enzymes, indicating potential liver damage.
5.1 Hepatotoxicity: “ALT or AST >3 × ULN were observed…” and “Aminotransferase elevations…”
Unsupported Statements
Patients with severe liver damage should discontinue bosentan to prevent further liver injury.
Label excerpt provides discontinuation criteria tied to hepatotoxicity symptoms or bilirubin ≥2×ULN, but does not use/justify the specific phrase “severe liver damage.”
Bosentan is contraindicated in pregnancy due to the risk of fetal harm.
The provided label excerpts do not include a pregnancy contraindication statement; only references to embryo-fetal toxicity/boxed warning/REMS are shown.
Bosentan exposure during pregnancy is associated with an increased risk of fetal malformations and other adverse outcomes.
The provided excerpts reference “Embryo-fetal Toxicity” but do not include details about fetal malformations or specific adverse outcomes.
Bosentan is not recommended for breastfeeding because its effects on the infant are unknown.
“8.2 Lactation” heading is present, but no breastfeeding recommendation or “effects…unknown” wording is included in the supplied excerpts.
Bosentan is primarily excreted through the kidneys.
No excretion/route statement (e.g., primarily renal) is present in the supplied excerpts.
Patients with severe kidney disease may experience increased levels of bosentan leading to toxicity.
The supplied renal impairment excerpt states effect is small and no dosing adjustment is required; it does not support severe-kidney toxicity/increased exposure claims.
Bosentan is associated with a significant increase in serum creatinine levels in patients with kidney disease.
No serum creatinine/creatinine increase findings are present in the supplied excerpts.
Patients with severe kidney disease should discontinue bosentan or use alternative treatments.
The supplied renal impairment excerpt states no dosing adjustment is required; it does not support discontinuation/alternatives for severe kidney disease.
Bosentan is contraindicated in patients with hepatic impairment.
The supplied hepatotoxicity excerpt discusses monitoring/discontinuation criteria but does not include a hepatic impairment contraindication statement.
Bosentan may exacerbate liver damage in patients with hepatic impairment.
Hepatotoxicity risk is discussed generally, but the supplied text does not specifically frame worsening as occurring “in patients with hepatic impairment.”
Bosentan may worsen anemia in patients with severe anemia.
Anemia appears as an adverse event in Table 3, but the supplied excerpts do not state worsening in “patients with severe anemia.”
Bosentan may exacerbate edema in patients with severe edema.
Edema appears as an adverse event in Table 3/fluid retention is referenced, but the supplied excerpts do not state exacerbation in “patients with severe edema.”
Patients taking bosentan should inform their healthcare provider about all medications they are taking to avoid potential interactions.
The supplied patient counseling excerpt does not mention interaction counseling; only general instruction to read Medication Guide is shown.
Bosentan increases the levels of warfarin.
No warfarin-specific interaction statement is included in the supplied excerpts.
Increased warfarin levels from bosentan are associated with an increased risk of bleeding.
No warfarin/bleeding risk linkage is included in the supplied excerpts.
Contradictions
Important Omissions
REMS availability/enrollment requirement tied to hepatotoxicity and embryo-fetal toxicity (Bosentan REMS).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims about pregnancy contraindication/fetal malformations, breastfeeding recommendations, and renal/hepatic severity-based discontinuation/toxicity are not supported by the provided label excerpts and could mislead clinical decision-making about high-risk populations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partly Aligned
Primary Issue
Multiple safety-critical statements are not supported by the supplied label excerpts, especially pregnancy/breastfeeding and renal/hepatic severity-based guidance, and several interaction details (warfarin) are not present.
Suggested Improvement
Restrict claims to text explicitly present in the provided label excerpts (e.g., hepatotoxicity monitoring/discontinuation criteria and drug interaction classes described). Remove or qualify statements that add specifics (pregnancy contraindication wording, fetal malformation details, breastfeeding unknown effects, renal creatinine/toxicity in severe disease, warfarin level/bleeding risk, hepatic impairment contraindication) that are not shown in the supplied excerpts.